Surprisingly strong orders support view that cycle has bottomed Soft guidance, but we think company ...
Enersense's execution of its new strategy appears to be successful.
Nettoomsättningen för det fjärde kvartalet uppgick till 1,2 MSEK (0,6), en ökning med 98,0 procent j...
Ramlösa Shipping (”Ramlösa” eller ”Bolaget”) publicerade den 28 februari år 2025 Bolagets delårsrapp...
Today on 28 February, Enrad AB (“Enrad” or “the Company”) published its interim report for Q4 2024.
Redeye is relieved to see that the CHMP reiterates its positive opinion of Lecanemab/Leqembi with no...
Redeye leaves a research update following Klaria Pharma’s recently published Q4 2024 report.
Redeye provides its brief comments on Ngenic’s Q4 report, which was better than expected.
The report was overall weaker than expected, primarily due to three out of four segments underperfor...
Redeye shares its initial thoughts on Dala Energi’s Q4 report, where the main highlight of the quart...
Revenue growth was -7% in Q4 y/y by excluding the largest customer.
Redeye provides its initial take on Heliospectra’s Q4 results, noting that while sales were below ex...
Redeye was hoping for slightly higher Q4 numbers, but quarterly variations are not unusual.
EBITDA 25% above driven by lower marketing costs Reiterates launch of Doro pre-installed sim cards i...
Redeye shares its initial take on Physitrack’s Q4 results, which came in above our expectations in t...
Redeye comments on FluoGuide’s Q4 2024 report. The company is approaching the interim readout of its...
Q-linea has improved access to growth capital and recently advanced the ASTar launch in Europe and t...
Redeye comments on Maximum Entertainment’s Q4-results where topline came in somewhat softer than exp...
Redeye updates its view on Verve Group following its Q4 2024 report, which came in stronger than exp...
Group net sales was EUR 28.8m in Q4 (Nordea est. EUR 29.